Johnson & Johnson to separate Orthopaedics business, create Depuy Synthes

Today we’re announcing our intent to separate our Orthopaedics business. We’re confident this move would further strengthen the focus of Johnson & Johnson on our six key growth areas – Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. It would also establish a standalone Orthopaedics business, operating as Depuy Synthes, that would be the largest, most comprehensive orthopaedics-focused company with leading market share positions across major product categories. Learn more: https://lnkd.in/ekMP46rg

  • No alternative text description for this image
Matt Murrisky

AI-Powered Operations Leader (MBA) | Orchestrating Teams, Financial Systems & Strategic Projects | Remote-Ready for Tech & FinTech

4d

This is a strategic pivot maximizing focus for both entities. J&J sharpens its innovation in those six core growth areas, while DePuy Synthes gains the independence needed to lead Orthopaedics. The real challenge is managing the organizational velocity of this change. My expertise is in rapid integration—translating ML-driven strategies into superior CX and clear stakeholder wins. Seeking a remote role where I can immediately bridge that gap between technical change and business execution.

Andrei Limanovskii

Pharma & healthcare | B2G & B2B | Medicine & hospital | Sales & business development

4d

This should bring positive results with a focus on orthopedics and, perhaps, traumatology as a separate area.👍

Steven LaCapria

Sales Professional | Medical Device & Surgical Sales | Territory Manager | Orthopedic Trauma & Spine | Strategic Account Growth | Former LPN | U.S. Navy Veteran

4d

Having spent years in orthopedics, I can appreciate the weight of this move. J&J’s decision to separate the ortho division signals both confidence and focus — creating space for each arm to innovate faster and serve patients better. Orthopedics has always been a cornerstone of surgical progress. It’ll be interesting to watch how this next chapter unfolds. #MedTech #Orthopaedics #SurgicalInnovation #HealthcareLeadership

Emily Simpson FCIPD

Global HR Director within fast growing businesses | Empowering organisational excellence & growth through strategic people-centric leadership | Coach

4d

Very interesting move. It will be fascinating to see how Orthopaedic competition of DePuy Synthes will react. Perhaps an opportunity to get ahead or make up some ground whilst the separation from J&J advances.

Paul Randall

Retired from DePuy Synthes Companies

4d

You always need to make adjustments as you move forward.

DePuy Synthes mold together with the signet of both sides and production. Good timing.

Brent Barker

Surgical sales Consultant in Sports Medicine, cross trained in Craniomaxillary Facial reconstruction and Orthopaedic Trauma.

4d

Very strategic move to bring a future positive impact on the Orthopaedic market.

Nassim Zaagoub

Trailblazing Data Maestro: Engineering New Frontiers in Analytics

4d

Johnson & Johnson’s plan to separate its orthopaedics business, establishing DePuy Synthes as an independent leader in the field, will sharpen J&J’s focus and investment on higher-growth, higher-margin markets like Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision, while enabling the new standalone company to pursue innovation and operational excellence in orthopaedics with greater agility.

Ebony N.

Partner Dentist | Cosmetic & Restorative Dentistry | Patient-Centered Care

16h

This should bring positive results with a focus on orthopedics and, perhaps, traumatology as a separate area.👍

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories